• Something wrong with this record ?

The Current Status of European and National Financial Sources for Clinical Research and Their Impact on Paediatric Non-commercial Clinical Trials: A Case Study of the Czech Republic

L. Horavova, K. Nebeska, L. Souckova, R. Demlova, P. Babula

. 2020 ; 54 (6) : 1461-1472. [pub] 20200605

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21019939

Grant support
CZECRIN (Identification code LM2015090) Ministerstvo Školství, Mládeže a Tělovýchovy

INTRODUCTION: Paediatric non-commercial interventional clinical trials (NICTs) are crucial for healthcare provision. In spite of the fact that current regulations and initiatives try to enhance the quantity and quality of paediatric NICTs, there are still shortcomings that need to be addressed in order to accelerate the conduct of relevant clinical trials in children. To improve the current landscape of paediatric clinical research, it is necessary to identify and analyse the main trends and shortcomings, along with their impact on national performance in paediatric NICTs and this is the aim of this work. METHOD: A retrospective systematic search of paediatric NICTs was performed on four international clinical trials registries. Entries were filtered by date from 01/01/2004 to 31/12/2017. Each identified paediatric NICT was screened and analysed for sponsors, funders, type of intervention, therapeutic area, design characteristics and associated publications. RESULTS: The search identified 439 unique NICTs. When stratifying the trials by enrolment ages, 86 trials were found involving the paediatric population. Most trials investigated the use of medicinal products and were focused on cancer or cardiovascular diseases. The most common sources of the funding were non-profit organizations. Furthermore, from the total number of completed trials, only half of them already published their results. CONCLUSION: The main shortcomings-specifically, ethical, methodological and, in particular, economic obstacles were identified. There is a continual need for greater support and collaboration between all major stakeholders including health policymakers, grant agencies, research institutions, pharmaceutical industries and healthcare providers at the national and international level.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019939
003      
CZ-PrNML
005      
20210830101539.0
007      
ta
008      
210728s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s43441-020-00173-9 $2 doi
035    __
$a (PubMed)32504401
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Horavova, L $u Department of Applied Pharmacy, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic. lhoravova@cvbf.net $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00, Brno, Czech Republic. lhoravova@cvbf.net
245    14
$a The Current Status of European and National Financial Sources for Clinical Research and Their Impact on Paediatric Non-commercial Clinical Trials: A Case Study of the Czech Republic / $c L. Horavova, K. Nebeska, L. Souckova, R. Demlova, P. Babula
520    9_
$a INTRODUCTION: Paediatric non-commercial interventional clinical trials (NICTs) are crucial for healthcare provision. In spite of the fact that current regulations and initiatives try to enhance the quantity and quality of paediatric NICTs, there are still shortcomings that need to be addressed in order to accelerate the conduct of relevant clinical trials in children. To improve the current landscape of paediatric clinical research, it is necessary to identify and analyse the main trends and shortcomings, along with their impact on national performance in paediatric NICTs and this is the aim of this work. METHOD: A retrospective systematic search of paediatric NICTs was performed on four international clinical trials registries. Entries were filtered by date from 01/01/2004 to 31/12/2017. Each identified paediatric NICT was screened and analysed for sponsors, funders, type of intervention, therapeutic area, design characteristics and associated publications. RESULTS: The search identified 439 unique NICTs. When stratifying the trials by enrolment ages, 86 trials were found involving the paediatric population. Most trials investigated the use of medicinal products and were focused on cancer or cardiovascular diseases. The most common sources of the funding were non-profit organizations. Furthermore, from the total number of completed trials, only half of them already published their results. CONCLUSION: The main shortcomings-specifically, ethical, methodological and, in particular, economic obstacles were identified. There is a continual need for greater support and collaboration between all major stakeholders including health policymakers, grant agencies, research institutions, pharmaceutical industries and healthcare providers at the national and international level.
650    _2
$a mladiství $7 D000293
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a dítě $7 D002648
650    12
$a klinické zkoušky jako téma $7 D002986
650    _2
$a farmaceutický průmysl $7 D004345
650    12
$a zdravotnický personál $7 D006282
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a nádory $7 D009369
650    _2
$a retrospektivní studie $7 D012189
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nebeska, K $u European Clinical Research Infrastructure Network (ECRIN), Paris, France $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00, Brno, Czech Republic
700    1_
$a Souckova, L $u European Clinical Research Infrastructure Network (ECRIN), Paris, France $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00, Brno, Czech Republic $u University Hospital St. Anne's Brno - International Clinical Research Center, Brno, Czech Republic
700    1_
$a Demlova, R $u European Clinical Research Infrastructure Network (ECRIN), Paris, France $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00, Brno, Czech Republic $u University Hospital St. Anne's Brno - International Clinical Research Center, Brno, Czech Republic $u Department of Clinical Trials, Masaryk Memorial Cancer Institute Brno, Brno, Czech Republic
700    1_
$a Babula, P $u Department of Applied Pharmacy, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00198808 $t Therapeutic innovation & regulatory science $x 2168-4804 $g Roč. 54, č. 6 (2020), s. 1461-1472
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32504401 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101539 $b ABA008
999    __
$a ok $b bmc $g 1690691 $s 1140385
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 54 $c 6 $d 1461-1472 $e 20200605 $i 2168-4804 $m Therapeutic innovation & regulatory science $n Ther Innov Regul Sci $x MED00198808
GRA    __
$a CZECRIN (Identification code LM2015090) $p Ministerstvo Školství, Mládeže a Tělovýchovy
LZP    __
$a Pubmed-20210728
Back

Find record

Citation metrics

Archiving options